Abstract

Evidence-based recommendations on nivolumab (Opdivo) for squamous cell carcinoma of the head and neck in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: More evidence on nivolumab is being collected, until September 2019. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a commercial access agreement for nivolumab. Contact mg-ukpasadmin@bms.com for details.